These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword. Magro F BioDrugs; 2010 Dec; 24 Suppl 1():1-2. PubMed ID: 21175227 [No Abstract] [Full Text] [Related]
25. [Anti-TNFα therapy and its implication in gynecology and obstetrics]. Ducarme G; Amate P; Seirafi M; Ceccaldi PF; Bouhnik Y; Luton D J Gynecol Obstet Biol Reprod (Paris); 2011 Oct; 40(6):492-7. PubMed ID: 21733638 [TBL] [Abstract][Full Text] [Related]
26. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Smith CH; Anstey AV; Barker JN; Burden AD; Chalmers RJ; Chandler DA; Finlay AY; Griffiths CE; Jackson K; McHugh NJ; McKenna KE; Reynolds NJ; Ormerod AD; Br J Dermatol; 2009 Nov; 161(5):987-1019. PubMed ID: 19857207 [No Abstract] [Full Text] [Related]
27. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Zelinkova Z; de Haar C; de Ridder L; Pierik MJ; Kuipers EJ; Peppelenbosch MP; van der Woude CJ Aliment Pharmacol Ther; 2011 May; 33(9):1053-8. PubMed ID: 21366638 [TBL] [Abstract][Full Text] [Related]
28. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. El Shabrawi-Caelen L; La Placa M; Vincenzi C; Haidn T; Muellegger R; Tosti A Inflamm Bowel Dis; 2010 Feb; 16(2):182-3. PubMed ID: 19462433 [No Abstract] [Full Text] [Related]
29. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis? Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350 [No Abstract] [Full Text] [Related]
30. [TNF-blockade--new strategy in difficult-to-treat asthma]. Dahlén SE; Millinger E; Skedinger M; Zetterström O; Dahlén B Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1946-8. PubMed ID: 18681378 [No Abstract] [Full Text] [Related]
31. [Immunobiology of chronic inflammatory bowel diseases]. Siegmund B; Zeitz M Dtsch Med Wochenschr; 2006 Nov; 131(47):2657-60. PubMed ID: 17109275 [No Abstract] [Full Text] [Related]
33. Anti-TNF Antibodies and Autophagy: A Hidden Nexus for a Successful Therapeutic Response? Genua M; Becker C; Vetrano S J Crohns Colitis; 2016 Mar; 10(3):237-8. PubMed ID: 26645640 [No Abstract] [Full Text] [Related]
34. Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile? Rojas-Villarraga A; Agudelo CA; Pineda-Tamayo R; Porras A; Matute G; Anaya JM Biomedica; 2007 Jun; 27(2):159-71. PubMed ID: 17713627 [TBL] [Abstract][Full Text] [Related]
35. Use of biologic agents in pediatric inflammatory bowel disease. Rosh JR Curr Opin Pediatr; 2009 Oct; 21(5):646-50. PubMed ID: 19629010 [TBL] [Abstract][Full Text] [Related]
36. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. Veerappan SG; Kennedy M; O'Morain CA; Ryan BM Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):588-9. PubMed ID: 18467922 [No Abstract] [Full Text] [Related]
37. Infliximab safety profile and long-term applicability in inflammatory bowel disease: clinical experiences from the eastern side of Europe. Molnár T; Farkas K; Nagy F; Szepes Z; Wittmann T Aliment Pharmacol Ther; 2010 May; 31(10):1152-3. PubMed ID: 20518754 [No Abstract] [Full Text] [Related]
38. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report. Borhani Haghighi A; Safari A Clin Neurol Neurosurg; 2008 Mar; 110(3):315-6. PubMed ID: 18053588 [No Abstract] [Full Text] [Related]
39. Tumor necrosis factor inhibitors for inflammatory bowel disease. Nielsen OH; Ainsworth MA N Engl J Med; 2013 Aug; 369(8):754-62. PubMed ID: 23964937 [No Abstract] [Full Text] [Related]
40. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Bucher C; Degen L; Dirnhofer S; Pless M; Herrmann R; Schraml P; Went P Gut; 2005 May; 54(5):732-3. PubMed ID: 15831931 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]